TCM
AMED

Tuttle Capital Management’s Amedisys AMED Stock Holding History

Tuttle Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,450
Closed -$315K – 96
2019
Q3 		$315K Buy
+2,450
New +$319K 0.08% 186

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Tuttle Capital Management's AMED Position: Q4 2019 in Review

Tuttle Capital Management sold out of Amedisys (AMED) in Q4 2019, closing a stake of 2,450 shares — an estimated $315K sold.

Tuttle Capital Management first reported a position in AMED in Q3 2019 and held it in 1 quarter. The position peaked at $315K in Q3 2019. 325 funds tracked by Wall St. Rank hold AMED as of Q4 2019.

  • Tuttle Capital Management reported no remaining Amedisys position as of Q4 2019 after selling out during the quarter.
  • Tuttle Capital Management sold 2,450 Amedisys shares in Q4 2019, an estimated $315K.
  • Tuttle Capital Management first reported a position in Amedisys in Q3 2019 and held it in 1 quarter.
  • Tuttle Capital Management's Amedisys position peaked at $315K in Q3 2019.
  • 325 funds tracked by Wall St. Rank held Amedisys as of Q4 2019.

Based on Tuttle Capital Management's 13F filing for Q4 2019, filed 13 Jan 2020.